

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

### STA Ixekizumab for treating active psoriatic arthritis after DMARDs

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Final appraisal determination

(when no ACD was issued)

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

During scoping, it was identified that there may be difficulties for some people to self-administer this technology, if they lack hand dexterity due to the effects of the arthritis. The committee considered that this issue related to additional resources for administering the treatment, rather than an equality issue within the equality legislation, and that there are already processes in place in clinical practice for people who are unable to self-administer subcutaneous treatments.
---

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No other potential equality issues were raised in the submissions, expert statements or academic report.
--

- |  |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

The committee noted that other appraisals in the same disease area had included recommendations that healthcare professionals should take into account skin colour/physical, sensory or learning disabilities or communication difficulties when using the PASI/PsARC. This is reflected in recommendations 1.3 and 1.4.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The equalities consideration are discussed in section 3.14 of the FAD, and are reflected in recommendations 1.3 and 1.4.

**Approved by Associate Director (name):** Helen Knight

**Date:** 06/08/2018